Simponi and Entyvio take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic that targets alpha-4-beta-7 integrin. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with favorable systemic safety. This guide walks through the simponi vs entyvio ulcerative colitis comparison.
Anti-TNF vs Gut-Selective Mechanism
Simponi binds TNF-alpha and reduces inflammation throughout the body and in the colon. Entyvio binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed colonic tissue, Entyvio quiets UC inflammation without meaningfully suppressing the immune system elsewhere. The golimumab vs vedolizumab UC distinction shapes speed of onset, safety profile, and long-term management.
UC Efficacy Data
Simponi's UC efficacy rests on PURSUIT-SC (induction) and PURSUIT-M (maintenance), which established golimumab as an effective SC anti-TNF for UC. Entyvio's UC efficacy was established in GEMINI-1 and confirmed in VARSITY, where vedolizumab was directly compared with adalimumab in a head-to-head trial. VARSITY showed Entyvio superior to Humira on clinical remission at 52 weeks (31.3% vs 22.5%), establishing vedolizumab as a strong first-line UC biologic. No head-to-head trial has directly compared Simponi with Entyvio in UC. Indirect comparisons, drawing on VARSITY's Humira benchmark, suggest Entyvio has advantage over anti-TNFs in biologic-naive UC patients.
Onset of Action
Simponi produces meaningful UC response by week 6 based on PURSUIT-SC. Entyvio's onset is slower, with meaningful response often not evident until week 10 to 14 and continued improvement through week 26. For UC patients with active symptoms who cannot tolerate a long ramp-up, Simponi's faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.
Safety and Infection Risk
Simponi carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection risk was lower. For UC patients with infection concerns, cancer history, or other risk factors for immunosuppression complications, Entyvio's narrower mechanism often looks more favorable.
Administration and Dosing
Simponi for UC uses 200 mg SC at week 0, 100 mg at week 2, and then 100 mg every 4 weeks for maintenance, per Janssen's prescribing information. Simponi is all-SC throughout. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg SC pen every 2 weeks, according to Takeda's dosing information. For UC patients comparing administration, Simponi is fully SC, while Entyvio requires IV induction before transitioning to IV or SC maintenance. Simponi's every-4-week cadence is between Entyvio's every-8-week IV cadence and its every-2-week SC option.
Extraintestinal Manifestations
Simponi, as an anti-TNF, treats UC-associated extraintestinal manifestations like peripheral arthritis, ankylosing spondylitis, and certain skin conditions. Entyvio's gut-selective action does not treat extraintestinal manifestations as effectively, which may limit its utility in patients with significant systemic inflammatory involvement. For UC patients with prominent joint disease or other extraintestinal findings, Simponi's systemic effect may be preferred.
Anti-TNF Experienced Patients
For UC patients who have already failed an anti-TNF, cycling to another anti-TNF like Simponi typically delivers lower response rates than changing mechanism classes to Entyvio. GEMINI-1 included anti-TNF experienced patients and showed meaningful response rates on Entyvio in this population. For anti-TNF experienced UC patients, Entyvio is generally preferred over cycling to Simponi.
Cost and Access
Simponi's SC formulation currently lacks widely available biosimilars in the US market. Entyvio is also branded with no biosimilar. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in UC. Manufacturer copay assistance programs exist for commercially insured patients on both drugs.
Choosing With Your GI
For a UC patient deciding between Simponi and Entyvio, Simponi tends to win on speed of onset, fully SC administration, extraintestinal manifestation coverage, and fewer infusion center visits. Entyvio tends to win on the narrowest systemic safety footprint, head-to-head UC data from VARSITY establishing superiority over Humira, and stronger performance in anti-TNF experienced patients. Your GI will weigh disease severity, prior biologic exposure, comorbidities, extraintestinal manifestations, and insurance coverage. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.